Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate

Verify with FDA CVM →

1,067 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,067
Total Reports
28
Deaths Reported
260.0%
Death Rate

Active Ingredients

Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate

Administration Routes

OralUnknownTopical

Species Affected

Dog 962
Unknown 104
Cat 1

Most Affected Breeds

Unknown 104
Retriever - Labrador 95
Retriever - Golden 84
Dog (unknown) 76
Shepherd Dog - Australian 52
Shih Tzu 40
Chihuahua 38
Crossbred Canine/dog 37
Shepherd Dog - German 36
Pit Bull 27

Most Reported Reactions

Vomiting 296
Diarrhoea 236
Lethargy (see also Central nervous system depression in Neurological) 118
UNPALATABLE 112
Behavioural disorder NOS 61
Emesis (multiple) 53
Lack of efficacy (endoparasite) - hookworm 49
Not eating 43
Other abnormal test result NOS 43
Lack of efficacy (ectoparasite) - flea 43
Seizure NOS 38
Product defect, product difficult to use/handle (see also 'Drug device difficult to use/handle') 36

Outcome Breakdown

Recovered/Normal
394 (40.9%)
Outcome Unknown
331 (34.3%)
Ongoing
211 (21.9%)
Died
20 (2.1%)
Euthanized
8 (0.8%)

Data Summary

Metric Value
Total adverse event reports 1,067
Reports involving death 28
Case-fatality rate (reported events) 260.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,067 adverse event reports referencing Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate, including 28 reports in which the animal died — a 260.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate. Reported administration routes include Oral, Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate reports are Dog (962 reports), Unknown (104 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Unknown (104), Retriever - Labrador (95), Retriever - Golden (84) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate are Vomiting (296), Diarrhoea (236), Lethargy (see also Central nervous system depression in Neurological) (118), UNPALATABLE (112). Of the 964 reports with a coded outcome, Recovered/Normal is the leading category at 40.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Lotilaner,Moxidectin,Praziquantel,Pyrantel Pamoate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial